To Cite:
Reece
A S. Restoring the Double Disconnect: Towards a Conceptual Reinstatement of Opiate Addiction as a High Risk Behaviour,
Int J High Risk Behav Addict.
2012
; 1(2):47-49.
doi: 10.5812/ijhrba.6936.
2.
Wodak AD. Public health and politics: the demise of the ACT heroin trial. Med J Aust. 1997; 167(7): 348-9[PubMed]
3.
Bernard C. Leçons sur le diabète et la glycogenèse animale. 1877;
4.
Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009; 105(1-2): 9-15[DOI][PubMed]
5.
Darke S, Duflou J, Torok M. The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend. 2010; 106(1): 1-6[DOI][PubMed]
6.
Smyth B, Hoffman V, Fan J, Hser YI. Years of potential life lost among heroin addicts 33 years after treatment. Prev Med. 2007; 44(4): 369-74[DOI][PubMed]
7.
Rosen D, Smith ML, Reynolds CF, 3rd. The prevalence of mental and physical health disorders among older methadone patients. Am J Geriatr Psychiatry. 2008; 16(6): 488-97[DOI][PubMed]
8.
Sadeghian S,
Darvish S,
Davoodi G,
Salarifar M,
Mahmoodian M,
Fallah N,
et al.
The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2007; 14(5): 715-7[DOI]
9.
Kim TW, Alford DP, Malabanan A, Holick MF, Samet JH. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend. 2006; 85(3): 258-62[DOI][PubMed]
10.
Neri S,
Bruno CM,
Pulvirenti D,
Malaguarnera M,
Italiano C,
Mauceri B,
et al.
Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology (Berl). 2005; 179(3): 700-4[DOI][PubMed]
12.
Reece AS, Davidson P. Deficit of circulating stem--progenitor cells in opiate addiction: a pilot study. Subst Abuse Treat Prev Policy. 2007; 2: 19-28[DOI][PubMed]
13.
Mousavi MR, Damghani MA, Haghdoust AA, Khamesipour A. Opium and risk of laryngeal cancer. Laryngoscope. 2003; 113(11): 1939-43[DOI]
14.
De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005; 579(10): 2035-9[DOI][PubMed]
15.
Sadeghian S, Dowlatshahi S, Karimi A, Tazik M. Epidemiology of opium use in 4398 patients admitted for coronary artery bypass graft in Tehran Heart Center. J Cardiovasc Surg (Torino). 2011; 52(1): 140-1
16.
Randall D,
Degenhardt L,
Vajdic CM,
Burns L,
Hall WD,
Law M,
et al.
Increasing cancer mortality among opioid-dependent persons in Australia: a new public health challenge for a disadvantaged population. Aust N Z J Public Health. 2011; 35(3): 220-5[DOI][PubMed]
17.
Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev. 2002; 38(3): 351-76[DOI]
18.
Anderson JE. A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol Biol Cell. 2000; 11(5): 1859-74[PubMed]
19.
Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011; 63(3): 772-810[DOI][PubMed]
Readers' Comments